key: cord-0720647-wghqmy49
authors: Mandolesi, Marco; Sheward, Daniel J.; Hanke, Leo; Ma, Junjie; Pushparaj, Pradeepa; Vidakovics, Laura Perez; Kim, Changil; Loré, Karin; Dopico, Xaquin Castro; Coquet, Jonathan M.; McInerney, Gerald; Karlsson Hedestam, Gunilla B.; Murrell, Ben
title: SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses
date: 2020-07-31
journal: bioRxiv
DOI: 10.1101/2020.07.31.228486
sha: 743b01c60003aa29e04dc49210be018395f7b413
doc_id: 720647
cord_uid: wghqmy49

The outbreak and spread of SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), the cause of coronavirus disease 2019 (COVID-19), is a current global health emergency and a prophylactic vaccine is needed urgently. The spike glycoprotein of SARS-CoV-2 mediates entry into host cells, and thus is a target for neutralizing antibodies and vaccine design. Here we show that adjuvanted protein immunization with SARS-CoV-2 spike trimers, stabilized in prefusion conformation 1, results in potent antibody responses in mice and rhesus macaques with neutralizing antibody titers orders of magnitude greater than those typically measured in serum from SARS-CoV-2 seropositive humans. Neutralizing antibody responses were observed after a single dose, with exceptionally high titers achieved after boosting. Furthermore, neutralizing antibody titers elicited by a dose-sparing regimen in mice were similar to those obtained from a high dose regimen. Taken together, these data strongly support the development of adjuvanted SARS-CoV-2 prefusion-stabilized spike protein subunit vaccines.

As of 22nd July 2020, at least 15 million cases of SARS-CoV-2 infection have been confirmed, with over 615,000 COVID-19 related deaths recorded 2 . Cases continue to spread globally despite unprecedented public health measures and lockdowns. An effective prophylactic vaccine is urgently required. Adjuvanted recombinant protein subunit vaccines have excellent safety profiles and represent a proven vaccine platform for eliciting protective immune responses to viral infections, including human papillomavirus (HPV), hepatitis B virus (HBV), and influenza A virus (IAV).

The spike glycoprotein of SARS-CoV-2 mediates receptor binding and entry into target cells, and is the primary target for vaccine design. The receptor binding domain (RBD) is a stable subunit within the spike glycoprotein ( Fig. 1A ) responsible for ACE2 binding [3] [4] [5] [6] [7] , that can be expressed as an independent domain [7] [8] [9] . While the RBD is a major target for neutralizing antibodies [10] [11] [12] , antibodies specific for spike epitopes outside of the RBD are also capable of neutralization 13, 14 .

To evaluate the use and immunogenicity of recombinant protein subunit vaccines for SARS-CoV-2 we immunized C57BL/6J mice (N=24) with either the spike ectodomain or RBD, expressed in 293-F cells. The RBD domain was expressed as an Fc-fusion protein, which was cleaved and the RBD subsequently purified by size-exclusion chromatography. The spike ectodomain was expressed as a prefusionstabilized variant with a C-terminal T4 trimerization domain, and the introduction of two stabilizing Proline mutations in the C-terminal S2 fusion machinery 1, 15, 16 . Highly pure and homogenous spike glycoprotein trimers were obtained by affinity purification followed by size-exclusion chromatography (Extended Data Fig. 1 ). Cryo-EM analysis of the spike preparation demonstrated that it was well-folded and maintained in the trimeric, prefusion conformation 17 , consistent with the original report 1 .

Mice were immunized with varying doses of antigen (range: 5 µg -50 µg) in Addavax (InvivoGen), a squalene-based oilin-water emulsion analogous to MF59. MF59 is licensed, safe and effective in humans 19 , and increases the immunogenicity of an influenza vaccine in the elderly 20 . Mice were boosted twice, at 3-week intervals, beginning 4 weeks after prime (Fig. 1A) . In both the low-dose (5 µg) and highdose (25 µg) groups, a single immunization with prefusionstabilized spike elicited a strong spike-specific IgG antibody response, detected by ELISA (Extended Data Fig. 2 ), as early as 4 weeks following the first immunization. RBD was less immunogenic, with weak to no detectable responses after the initial prime. However, seroconversion was evident in all mice after the first boost with RBD.

To determine whether the antibody responses elicited were neutralizing, we used a SARS-CoV-2 pseudotyped virus neutralization assay. In spike-immunized mice, neutralizing responses (ID50 100) were already detectable in four of ten mice after a single dose ( Fig. 1B and Extended Data Fig. 3 ). All spike-immunized mice developed potent neutralizing antibody responses (median ID50 1,600) after the first boost, which further increased in potency (median ID50 25,000) after the second boost. In contrast, RBD-immunized mice developed consistent neutralizing antibody responses only after the second boost, with a median ID50 neutralizing anti- A. Two SARS-CoV-2 protein immunogens were evaluated: stabilized spike trimer, and receptor binding domain (RBD). Mice (N=24) were immunized and humoral immune responses were followed longitudinally to compare stabilized spike vs RBD immunogens at several doses. B. Serial dilutions of serum from immunized mice were assessed for neutralization of SARS-CoV-2 pseudotyped lentiviruses harbouring a luciferase reporter gene, and the ID50 titers were calculated as the reciprocal dilution where infection (RLU) was reduced by 50% relative to infection in the absence of serum. The geometric mean ID50 for each group is displayed. -(unimmunized mice -open circles); S+ (5µg stabilized spike -orange); S++ (25µg stabilized spike -red); RBD+ (5µg RBD -cyan); RBD++ (25µg RBD -blue); RBD+++ (50µg RBD -navy). ID50 titers below the limit of detection (45 or 90 depending on sample availability) are displayed as 45. ID50 titers in seropositive donors (black) in Castro Dopico et al. 18 determined using the same assay, and the median and interquartile range is highlighted in grey across the background.

body titer across all groups of 5,300. The substantial enhancement of the virus neutralizing activity observed after the second RBD boost warrants further investigation. Across all groups, spike-specific IgG titers correlated strongly with pseudovirus neutralization, though neutralization was detectable only above a threshold EC50 (Extended Data Fig  5A) . Interestingly, RBD medium (25 µg) and high (50 µg) doses elicited neutralizing antibody responses with similar ID50 values to those from the spike groups, but with a significantly flatter slope (p=0.0002), such that they were less neutralizing at higher concentrations (see Extended Data Fig.  4 ). This could potentially be a result of epitopes on soluble RBD being subject to competition in the context of intact spike trimer. This also suggests an additional advantage of spike immunization over RBD alone, as incomplete neutralization may compromise sterilizing immunity. Next, we immunized three rhesus macaques (Macaca mulatta) with adjuvanted trimeric prefusion-stabilized spike glycoprotein over approximately 4-week intervals ( Fig. 2A) , and characterized the titers and kinetics of binding and neutralizing antibodies. Macaques were immunized intramuscularly with 100 µg of spike protein in 75 µg Matrix-M, a saponin-based adjuvant developed for clinical use 21 (Novavax AB). Neutralizing antibody responses were already detectable 2 weeks after a single dose (ID50 titers ranging from 150-420) with titers retained at 4 weeks (Fig. 2C) . Two weeks after a first boost, the neutralizing antibody responses were extremely potent, exceeding ID50 titers of 20,000 in all three macaques. An additional boost 3 weeks later did not raise the neutralization potency above that obtained with just two immunizations, suggesting a third dose is not needed to achieve highly potent neutralizing antibody responses following spike protein-based vaccination. After two prefusion-stabilized spike protein immunizations, geometric mean neutralizing antibody titers in macaques were approximately two orders of magnitude more potent than that of sera from SARS-CoV-2 seropositive humans (Fig. 2C ). These were also substantially higher than those elicited by other immunization platforms that afforded macaques partial or complete protection from challenge 22, 23 . In three recent phase I human trials, neutralizing antibody titers elicited by mRNA or adenovirus-vectored vaccines were similar to 24, 25 or well below 26 those from convalescent sera. The spike-directed IgG binding titers elicited in the macaques ( Fig. 2B ) correlated strongly with the virus neutralizing activity (R2 = 0.9478, Extended Data Fig. 5 ) and the rapid development of potent virus neutralizing antibody responses in macaques after a single dose suggested a minimal requirement for somatic hypermutation (SHM) of the response. This is consistent with recent data showing that neutralizing monoclonal antibodies isolated from SARS CoV-2 convalescent individuals display low levels of SHM 12, 27, 28 . The polyclonality, antibody germline VDJ usage, and level of SHM that characterizes vaccine-induced SARS CoV-2 spike-induced antibody responses will be a matter of interest, both in the macaque model and in human vaccine trials.

Neutralizing antibody titers have varied substantially across different vaccine platforms. In animal models, inactivated virus, DNA, and adenovirus-vectored vaccines elicited neutralizing antibody titers similar to or lower than those seen in convalescent sera 22, 23, 29 . While high dose mRNA-based immunizations elicited potent neutralizing antibody responses in mice 30 , neutralizing antibody titers elicited in phase I human trials were markedly lower 25 . Immunization of mice with mRNA encoding stabilized spike led to reduced or undetectable viral loads in the lungs and nasal turbinates, in a dose-dependent manner, and susceptible transgenic mice were protected from lethal challenge 30 . Other preclinical vaccine studies using genetic platforms elicited immune responses that protect against disease but not against infection. For example, RBD-and spike-encoding DNA vaccines led to reduced viral loads in the nose and lungs of challenged macaques 22, 23 . Titers of neutralizing antibodies correlate strongly with protection in a number of vaccine settings [31] [32] [33] . For SARS-CoV-2, passive transfer of neutralizing monoclonal antibodies provided partial or complete protection of animal models, in a dose-dependent manner 11, 34, 35 . Here, we show in mice and macaques that neutralizing antibody titers elicited by both spike and RBD protein subunit immunization were orders of magnitude higher than those we detected in SARS-CoV- 2 seropositive humans. This reinforces that vaccination can induce more reliable immunity in the population than natural infection. Since it is expected that binding and neutralizing antibody titers decrease from their peak with time, high initial titers will most likely translate into longer lasting protection. Here we show in animal models (mice and macaques) that immunization with RBD or prefusion-stabilized trimeric SARS-CoV-2 spike proteins elicits potent neutralizing antibody responses. Further, we find that neutralizing responses are more readily elicited and more potent with the stabilized trimeric spike glycoprotein than with RBD. Importantly, we show that neutralizing antibodies were elicited across animal models, using different immunization routes and with different adjuvants, highlighting that the SARS-CoV-2 spike protein represents a robust immunogen. Importantly, significant neutralizing antibody titers arose in non-human primates after a single dose with an adjuvanted spike subunit protein vaccine. Production of prefusion-stabilized spike at an industrial scale to meet global demand in a rapid time frame may be challenging. However, a number of groups have recently identified additional stabilizing mutations and protocols that dramatically improve protein stability and expression yields [39] [40] [41] . Further, we show in mice that a dose-sparing regimen with 5-fold less spike antigen elicited neutralizing antibodies at a similar titer. The potential to leverage existing infrastructure and manufacturing capacity for licensed vaccines could also accelerate production and rollout.

Here we report that mice and macaques immunized with adjuvanted prefusion-stabilized spike developed potent neutralizing antibody responses. These are stronger than those previously reported to confer partial or complete protection in animal models, and substantially more potent than those from three recent phase I human trials of mRNA or adenovirusvectored vaccines [24] [25] [26] . Taken together, these results support the development of protein subunit vaccines to immunize against SARS-CoV-2.

Sweden, for generously making the Matrix-M adjuvant available. We additionally thank James Voss and Deli Huang for reagents. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101003653 (CoroNAb), to GBKH, GM, and BM, and from the Swedish Research Council to GBKH, GM, and BM. Two control mice were not immunized. Tail bleeds were taken prior to each immunization. Whole blood was allowed to clot at room temperature, and serum was separated by centrifugation, heat inactivated at 56°C for 1 hour, and stored at -20°C until use. . EC50 titers were calculated using a Bayesian logistic curve fitting approach, allowing plate-specific minimum and maximum sigmoid parameters to account for differences between plates, and sample specific slope and offset parameters. EC50 titers were calculated from the posterior median value midway between the plate minimum and maximum. Macaque ELISAs: ELISA plates were coated with prefusion-stabilized spike protein as above, washed, and blocked with 5%(w/v) non-fat milk powder in 1x PBS. Thereafter, 10-fold serial dilutions (starting at 1:200) of plasma in blocking buffer were added, and plates were incubated for 2 hours at room temperature. Plates were washed and antibody-antigen interaction was detected using HRP-conjugated anti-monkey IgG Fc (#GAMon/IgG(Fc)/PO Nordic MUbio) diluted 1:20,000 in PBS-T. Plates were developed using 50 µl of 3,3',5,5"-tetramethylbenzidine substrate so-lution (Invitrogen) per well and stopped using 50 µl of 1M sulphuric acid per well. OD was read at 450nm in an Asys Expert 96 plate reader (Biochrom). Every washing step was performed with 0.05% PBS-T. All experiments were conducted in triplicates. EC50 titers were calculated as for the mice. Pseudotyped neutralization assays: Pseudotyped neutralization assays were adapted from protocols previously validated to characterize the neutralization of HIV 42 but with the use of HEK293T-ACE2 cells, as previously described 17 . All cell lines were cultured in a humidified 37°C incubator (5% CO2) in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% Fetal Bovine Serum and 1% Penicillin/Streptomycin, and were passaged when nearing confluency using 1X Trypsin-EDTA. All cell lines tested negative for mycoplasma by PCR. Pseudotyped lentiviruses displaying the SARS-CoV-2 spike protein (harboring an 18 amino acid truncation of the cytoplasmic tail) and packaging a luciferase reporter gene were generated by the co-transfection of HEK293T cells using Lipofectamine 3000 (Invitrogen) per the manufacturer's protocols. Media was changed 12-16 hours after transfection, and pseudotyped viruses were harvested at 48-and 72-hours post transfection, filtered through a 0.45 µm filter, and stored at -80°C until use. Pseudotyped viruses sufficient to generate 100,000 RLUs were incubated with serial dilutions of serum for 60 min at 37°C in a 96-well plate, and then 15,000 HEK293T-ACE2 cells were added to each well. Plates were incubated at 37°C for 48 hours, and luminescence was then measured using Bright-Glo (Promega) per the manufacturer's protocol, on a GM-2000 luminometer (Promega). ID50 titers were calculated as the reciprocal serum dilution at which RLUs were reduced by 50% relative to control wells in the absence of serum. and macaque (B) sera. Neutralization ID50 below the limit of detection is plotted as the assay's limit of detection (45).

COVID-19 situation update worldwide

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensinconverting enzyme 2

The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction

Disease-associated antibody phenotypes and probabilistic seroprevalence estimates during the emergence of SARS-CoV-2

Juergen Zorn, and Renald Hennig. Safety of MF59 adjuvant

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

Evaluation of a virosomal H5N1 vaccine formulated with matrix m™ adjuvant in a phase I clinical trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind

An mRNA vaccine against SARS-CoV-2 -preliminary report

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind

Analysis of a SARS-CoV-2-Infected individual reveals development of potent neutralizing antibodies with limited somatic mutation

Correlates of protection induced by vaccination

Vaccine-Induced protection from homologous tier 2 SHIV challenge in nonhuman primates depends on Serum-Neutralizing antibody titers

A metaanalysis of passive immunization studies shows that Serum-Neutralizing antibody titer associates with protection against SHIV challenge

Yingmei Feng, Chuan Qin, Chengfeng Qin, Ronghua Jin, and X Sunney Xie. Potent neutralizing antibodies against SARS-CoV-2 identified by High-Throughput Single-Cell sequencing of convalescent patients' B cells

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

Draft landscape of COVID-19 candidate vaccines

Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

Rainer Doffinger, John A G Briggs, and The CITIID-NIHR COVID-19 BioResource Collaboration

Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays. bioRxiv

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. bioRxiv

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1

We thank Dr. Bengt Eriksson and all personnel at Astrid Fagraeus laboratory for expert assistance with rhesus macaques. We also thank Novavax, AB, Uppsala,